318 related articles for article (PubMed ID: 32796130)
1. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
[TBL] [Abstract][Full Text] [Related]
3. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
[TBL] [Abstract][Full Text] [Related]
4. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis.
Fang B; McKeon A; Hinson SR; Kryzer TJ; Pittock SJ; Aksamit AJ; Lennon VA
JAMA Neurol; 2016 Nov; 73(11):1297-1307. PubMed ID: 27618707
[TBL] [Abstract][Full Text] [Related]
7. Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers.
McKeon A; Shelly S; Zivelonghi C; Basal E; Dubey D; Flanagan E; Madhavan AA; Mariotto S; Toledano M; Tracy JA; Zekeridou A; Pittock SJ
Ann Clin Transl Neurol; 2021 Feb; 8(2):425-439. PubMed ID: 33369283
[TBL] [Abstract][Full Text] [Related]
8. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
Sechi E; Zekeridou A
J Thorac Oncol; 2021 Mar; 16(3):381-394. PubMed ID: 33188910
[TBL] [Abstract][Full Text] [Related]
9. Predictive models in the diagnosis and treatment of autoimmune epilepsy.
Dubey D; Singh J; Britton JW; Pittock SJ; Flanagan EP; Lennon VA; Tillema JM; Wirrell E; Shin C; So E; Cascino GD; Wingerchuk DM; Hoerth MT; Shih JJ; Nickels KC; McKeon A
Epilepsia; 2017 Jul; 58(7):1181-1189. PubMed ID: 28555833
[TBL] [Abstract][Full Text] [Related]
10. Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Data Brief; 2024 Apr; 53():110062. PubMed ID: 38317734
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma.
Zekeridou A; McKeon A; Lennon VA
JAMA Neurol; 2016 Jul; 73(7):853-9. PubMed ID: 27135398
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments.
Zekeridou A; Majed M; Heliopoulos I; Lennon VA
Thorac Cancer; 2019 Apr; 10(4):1001-1004. PubMed ID: 30810271
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Zekeridou A; Kryzer T; Guo Y; Hassan A; Lennon V; Lucchinetti CF; Pittock S; McKeon A
Neurology; 2019 Aug; 93(8):e815-e822. PubMed ID: 31315972
[TBL] [Abstract][Full Text] [Related]
14. Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy.
Zekeridou A; Lennon VA
Mayo Clin Proc; 2019 Sep; 94(9):1865-1878. PubMed ID: 31358366
[TBL] [Abstract][Full Text] [Related]
15. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
Klein CJ; Lennon VA; Aston PA; McKeon A; O'Toole O; Quek A; Pittock SJ
JAMA Neurol; 2013 Feb; 70(2):229-34. PubMed ID: 23407760
[TBL] [Abstract][Full Text] [Related]
16. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic neuronal intermediate filament autoimmunity.
Basal E; Zalewski N; Kryzer TJ; Hinson SR; Guo Y; Dubey D; Benarroch EE; Lucchinetti CF; Pittock SJ; Lennon VA; McKeon A
Neurology; 2018 Oct; 91(18):e1677-e1689. PubMed ID: 30282771
[TBL] [Abstract][Full Text] [Related]
18. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility.
Dhamija R; Tan KM; Pittock SJ; Foxx-Orenstein A; Benarroch E; Lennon VA
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):988-92. PubMed ID: 18599359
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.
Lucchinetti CF; Kimmel DW; Lennon VA
Neurology; 1998 Mar; 50(3):652-7. PubMed ID: 9521251
[TBL] [Abstract][Full Text] [Related]
20. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
